Linked Life Data

7044791

Source:http://linkedlifedata.com/resource/pubmed/id/7044791

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1982-8-26
pubmed:abstractText
Twenty-three patients with Peyronie's disease have been treated with the new anti-inflammatory metalloprotein drug orgotein, which exhibits pronounced superoxide dismutase activity. Administration was done into the indurated areas of the penis by a special syringe. Evaluation of signs and symptoms included measurement of the induration size and consistency as well as the degree of the deviation of the penis. The patients responded well to orgotein therapy, especially regarding the loss of pain on erection. On long term results also a diminishment of the induration size and penis deviation on erection was observed; the drug administered intraplaqueally was of outstanding safety.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0140-1610
pubmed:author
pubmed:issnType
Print
pubmed:volume
4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
250-9
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1981
pubmed:articleTitle
Orgotein, a new drug for the treatment of Peyronie's disease.
pubmed:publicationType
Journal Article, Clinical Trial